Dr Jan Burger speaks with ecancertv at BSH 2016 about the crosstalk targeting therapies presenting an alternative to chemotherapy in treating CLL.

These include kinase inhibitors, which enable signals from the microenvironment which upregulate B and T Cell presence towards tumours.

With regards to drug resistance, Dr Burger describes the need for strategies in novel treatment schemes to manage and reduce risk to patients.

For more from Dr Burger on CLL, you can watch another interview with him regarding the RESONATE2 trials of frontline ibrutinib here.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.